metaPreg - Teriflunomide during pregnancy

Teriflunomide

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Growth parameters and prematurity
Low birth weight (< 2500g)	1.66 [0.49, 5.70]	-	1 study	98	23	not evaluable	ROB	-
Preterm (< 37 weeks)	0.25 [0.01, 4.12]	-	1 study	94	23	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	1.01 [0.37, 2.74]	-	1 study	255	23	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	0.50 [0.03, 8.44]	-	1 study	48	23	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	0.82 [0.20, 3.44]	-	1 study	81	47	not evaluable	ROB	-
Elective/induced termination of pregnancy	4.97 [2.75, 8.99]	-	1 study	236	47	not evaluable	ROB	9.41 [4.94; .]
Late intrauterine deaths (> 22 weeks)	1.56 [0.09, 27.10]	-	1 study	10	47	not evaluable	ROB	-
Therapeutic terminations of pregnancy	1.57 [0.21, 11.93]	-	1 study	22	47	not evaluable	ROB	-
Hide endpoints reported in only one study ...